These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7937536)

  • 1. Interaction between ciprofloxacin and metal cations: its influence on physicochemical characteristics and antibacterial activity.
    Li RC; Nix DE; Schentag JJ
    Pharm Res; 1994 Jun; 11(6):917-20. PubMed ID: 7937536
    [No Abstract]   [Full Text] [Related]  

  • 2. [Synthesis and antibacterial activity of N-(aroylalkyl) ciprofloxacin].
    Hu AX; Wang YT; You TB
    Yao Xue Xue Bao; 2007 Aug; 42(8):854-7. PubMed ID: 17944234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The physicochemical and antibacterial properties of ciprofloxacin-Mg2+ complex.
    Adepoju-Bello AA; Coker HA; Eboka CJ; Abioye AO; Ayoola GA
    Nig Q J Hosp Med; 2008; 18(3):133-6. PubMed ID: 19062475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic investigation of the reduction in antimicrobial activity of ciprofloxacin by metal cations.
    Ma HH; Chiu FC; Li RC
    Pharm Res; 1997 Mar; 14(3):366-70. PubMed ID: 9098883
    [No Abstract]   [Full Text] [Related]  

  • 5. Single-walled carbon nanotubes-ciprofloxacin nanoantibiotic: strategy to improve ciprofloxacin antibacterial activity.
    Assali M; Zaid AN; Abdallah F; Almasri M; Khayyat R
    Int J Nanomedicine; 2017; 12():6647-6659. PubMed ID: 28924348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
    Parte AC; Smith JT
    Microbios; 1994; 80(322):31-9. PubMed ID: 7854197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of novel 5-fluoro analogues of norfloxacin and ciprofloxacin.
    Moran DB; Ziegler CB; Dunne TS; Kuck NA; Lin YI
    J Med Chem; 1989 Jun; 32(6):1313-8. PubMed ID: 2498519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antibacterial activity of catecholate-ciprofloxacin conjugates.
    Fardeau S; Dassonville-Klimpt A; Audic N; Sasaki A; Pillon M; Baudrin E; Mullié C; Sonnet P
    Bioorg Med Chem; 2014 Aug; 22(15):4049-60. PubMed ID: 24972726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles.
    Dillen K; Vandervoort J; Van den Mooter G; Verheyden L; Ludwig A
    Int J Pharm; 2004 May; 275(1-2):171-87. PubMed ID: 15081148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of ciprofloxacin.
    Ferrara A; Donnetta A; Grassi FA; Gialdroni Grassi G
    Chemioterapia; 1987 Jun; 6(2 Suppl):130-1. PubMed ID: 3151333
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
    Bowker KE; Wootton M; Rogers CA; Lewis R; Holt HA; MacGowan AP
    J Antimicrob Chemother; 1999 Nov; 44(5):661-7. PubMed ID: 10552983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA interactions and promotion in antibacterial activities of ciprofloxacin drug due to formation of mixed-ligand complexes of oxovanadium(IV).
    Patel MN; Patel SH; Chhasatia MR; Desai CR
    Nucleosides Nucleotides Nucleic Acids; 2010 Mar; 29(3):200-15. PubMed ID: 20408051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An inexpensive infrared growth sensor array for detection of bacterial antibiotic susceptibility.
    Mason DJ; Lloyd AL; Lloyd D
    FEMS Microbiol Lett; 1993 Aug; 111(2-3):251-4. PubMed ID: 8405933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA cleavage, binding and intercalation studies of drug-based oxovanadium(IV) complexes.
    Patel MN; Chhasatia MR; Patel SH; Bariya HS; Thakkar VR
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):715-21. PubMed ID: 18951284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of a spectrophotometric method for the determination of post-antibiotic effect and comparison with viable counts in agar.
    Domínguez MC; de La Rosa M; Borobio MV
    J Antimicrob Chemother; 2001 Apr; 47(4):391-8. PubMed ID: 11266409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis.
    Lagast H; Husson M; Klastersky J
    J Antimicrob Chemother; 1985 Sep; 16(3):341-7. PubMed ID: 2932416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine to MIC values of ciprofloxacin in ciprofloxacin resistant gram-negative bacteria].
    Coban AY; Bayram Z; Sezgin FM; Durupinar B
    Mikrobiyol Bul; 2009 Jul; 43(3):457-61. PubMed ID: 19795621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the fractional maximal effect method: comparative interaction studies of ciprofloxacin and protein synthesis inhibitors.
    Li RC; Nix DE; Schentag JJ
    J Chemother; 1996 Feb; 8(1):25-32. PubMed ID: 8835104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.